From Blood Pressure Control to Weight-Centered Hypertension Management: The Emerging Role of Incretin-Based Therapies
DOI:
https://doi.org/10.62838/amsm-2026-0037Keywords:
arterial hypertension; obesity; GLP-1; semaglutide; tirzepatide; incretins; weight loss; cardiovascular risk.Abstract
Obesity and hypertension often coexist in the same person and reinforce each other. Treatment of hypertension in people with obesity has been based mainly on lifestyle changes and the gradual addition of antihypertensive drugs. The development of GLP-1 receptor agonists and combined GIP/GLP-1 agonists has transformed the treatment of obesity, with implications beyond weight loss. These therapies can produce significant weight loss, but they also lower blood pressure and improve several other cardiometabolic risk factors. Recent data suggest that the reduction in blood pressure is largely related to weight loss, but is not necessarily fully explained by it. Effects on natriuresis, endothelial function, inflammation, neurohormonal activity, and circulating volume may represent additional mechanisms. In practice, this creates a new situation: a patient who loses significant weight may need less antihypertensive therapy. Our aim is to examine the relationship between obesity and hypertension, the clinical evidence on semaglutide, tirzepatide, and newer incretin-based therapies, as well as the possible transition from an approach focused solely on blood pressure toward management that also addresses adiposity as part of the disease mechanism.
Downloads
Downloads
Published
How to Cite
License
Copyright (c) 2026 Ergita Nelaj, Irida Kecaj, Kei Xixhabesi, Margarita Gjata

This work is licensed under a Creative Commons Attribution 4.0 International License.
Acta Marisiensis Seria Medica provides immediate open access to its content under the Creative Commons BY 4.0 license.






